Latest News Feed
The DEA Diversion Control Problem: A Hidden Threat to U.S. Pharmaceutical Manufacturing ?
Take the case of MMJ BioPharma Cultivation - despite submissions of FDA Investigational New Drug (IND) applications and Orphan Drug Designation approval for treating Huntington's Disease - has been blocked from manufacturing cannabis-derived pharmaceuticals by the DEA, under the leadership of Deputy Administrator Thomas Prevoznik.
From Plant to Pill: MMJ-001 Marks a Pharmaceutical First in Cannabis Medicine with FDA-Grade Formulation for a Devastating Neurological Disorder while awaiting final FDA approval for use in clinical trials.
Poisoned Cannabis, Zero DEA Oversight
The DEA's mission statement is a sham under Thomas Prevoznik's watch. Americans are being poisoned by untested state cannabis operators while terminal patients are denied potential cures.
While the DEA's Thomas Prevoznik Turned a Blind Eye, American Cannabis Users Were Poisoned: How the DEA Regulatory Failure and Inaction Enabled a Public Health Crisis.
The DEA's in-house administrative court system has been dealt a severe blow by recent U.S. Supreme Court rulings. Axon v. FTC (2023) and Jarkesy v. SEC (2024) have unequivocally declared this system unconstitutional, effectively rendering years of DEA imposed delays and administrative hearings illegitimate. In a significant move, the Department of Justice has formally refused to defend this unconstitutional system, potentially exposing current and former DEA leadership to civil rights litigation and heightened judicial oversight.
While Chinese cartels built a marijuana empire across at least six states, MMJ-a Rhode Island-based company with FDA orphan drug status-was left to rot in a bureaucratic black hole engineered by DEA Diversion officials Matthew Strait, Thomas Prevoznik, Anne Milgram and Aarathi Haig.
Retirements Reported in DEA's DIVERSION as "DOGE CASUALTIES".
DEA Faces Scrutiny Over Delays in Medical Cannabis Research.
As MMJ BioPharma Cultivation unleashes a legal reckoning, the DEA's unconstitutional Administrative Law system collapses under Supreme Court rulings-forcing Department Of Justice to retreat, leaving DEA officials scrambling for cover. DEA diversion officials will be remembered on its "wall of DISHONOR" for blocking marijuana medicine to suffering patients in need.
This is more than a marijuana case. It's a constitutional case. It's a test of whether the DEA is still accountable to the courts, to the people, and to the law.
"If the DEA believes it can ignore the Supreme Court, then no American is safe from administrative tyranny," Duane Boise warned. " MMJ will fight. And we will win."
Watch the Senate hearing: https://dai.ly/x9j0le4
Despite MMJ's full regulatory compliance and orphan drug status from the FDA, its DEA manufacturing registration (GROW MARIJUANA) remains stonewalled inside a DEA administrative court system now deemed unconstitutional under Axon and Jarkesy. Meanwhile, tribal transit networks face virtually no enforcement-exposing a hypocritical and dangerous DEA double standard.
Judge Mulrooney's decision may have handed MMJ BioPharma Cultivation a defeat inside the DEA's walls, but in doing so, he may have handed MMJ a powerful victory in federal court. The record of constitutional violations and DEA violations is now preserved - the "Axon-Jarkesy defense"is primed - and the very administrative law judge system the DEA clings to may not survive scrutiny.
Judge Mulrooney's ruling epitomizes the DEA's institutional resistance to cannabis reform, prioritizing bureaucratic obstruction over public health and constitutional rights. As MMJ fights back in federal court, the case exposes a system rigged against progress-one where patients, science, and fairness are collateral damage in the failed DEA war on marijuana research.
Illegal THC on every corner, Illegal grow ops in plain sight, Yet the DEA continues to block MMJ BioPharma Cultivation's FDA sanctioned application to produce pharmaceutical-grade cannabis pending since 2018.
"The era of rogue DEA regulators must end," said Duane Boise. "If DEA administrator nominee wants to restore credibility, he must start by naming and removing the Biden-era ‘Do-Nothing' team."
Two Schedule I drugs. Two research tracks. One DEA double standard.
MMJ BioPharma Cultivation's FDA sanctioned cannabis research has been stonewalled for seven years. Meanwhile, Texas launches state-funded ibogaine trials with full political support and zero DEA obstruction.
Is federal drug policy about science or selective enforcement?
With Congress potentially repealing the Rohrabacher-Blumenauer Amendment, FDA-Approved Cannabis Medicines Are the Only Path Forward.
DEA Back to Training School, DEA Bureaucrat Blocks Science While Ignoring their Own TRAINING Manual.
DEA Assistant Administrators and attorney needs a summer assignment, and MMJ BioPharma Cultivation has a suggestion: go back and read your own policy statement and training manual.
Terrance Cole's First Test: Will He Restore DEA Diversion To Legitimacy
As the DEA Diversion spirals into constitutional crisis, all eyes now turn to incoming Administrator Terrance Cole. With the Supreme Court, DOJ, and Congress aligned on the illegality of the agency's ALJ system, Cole faces a clear mandate: dismantle the DEA's kangaroo court framework, remove corrupt leadership like Thomas Prevoznik, Matthew Strait and attorney Aarathi Haig, restore sound marijuana policy and return the agency to the rule of law. His next moves will determine whether the DEA Diversion can be salvaged-or whether it must be restructured from the ground up.
Terrance Cole, the nominee for Administrator of the U.S. Drug Enforcement Administration (DEA), stands at a pivotal juncture with the opportunity to address longstanding issues related to the agency's handling of cannabis policy.
The DEA's In-House Forum Takes Another Hit
While the Department of Justice has withdrawn its defense of the DEA, the DEA continues to conduct hearings under this unconstitutional framework. Attorney General Pam Bondi wrote in her recent notice to the courts:
"The Department has reviewed recent Supreme Court precedent and concluded that the existing structure of DEA's ALJs does not meet constitutional muster. Effective immediately, we will no longer defend this system in litigation and have notified federal courts accordingly."
Duane Boise MMJ CEO opined “Now all eyes turn to DEA Administrator-nominee Terrance Cole. Thus far, his public marijuana statements have been evasive, his confirmation answers noncommittal, and his track record steeped in anti-cannabis fearmongering. However, as the DEA boss, he needs to stop the clown show in comparing cannabis to methamphetamine with no clinical basis and distributing memes claiming cannabis lowers sperm count by 50%, despite contradictory evidence”.
"The Drug Enforcement Administration (DEA) is embroiled in a glaring contradiction: While federally compliant medical cannabis researchers like MMJ BioPharma Cultivation remain paralyzed by bureaucratic delays, U.S. recreational cannabis companies are openly exporting products, intellectual property and money to Europe-flouting federal law with no DEA intervention", stated Duane Boise, CEO MMJ. This double standard exposes a system prioritizing corporate profits over scientific progress and public health, undermining the DEA's mandate under the Controlled Substances Act (CSA).
As Former White House Drug Czar Rahul Gupta revealed DEA intentional sabotage, will DEA Administrator Nominee Terrance Cole Address the Marijuana Crisis? Bureaucratic Inaction and Medical Delays Demand Accountability.
"The irony is glaring," said Boise. "The DEA blocks lawful drug development while cartels profit. The agency is both gatekeeper and roadblock-and now, a constitutional liability." The DEA's own 2025 National Drug Threat Assessment admits that illicit cannabis operations tied to foreign cartels thrive in legalized states, operating under state licenses while DEA policy bureaucrats Thomas Prevoznik and Matthew Strait remains unchecked.
The appearance of Thomas Prevoznik and Matthew Strait as thought leaders in global drug policy is more than just tone-deaf-it's dangerous. It validates a failed regulatory approach that punishes innovation, undermines public health, and sidelines scientific progress for political convenience
"The DEA is creating a regulatory paradox where science is stifled and illegal activity is tolerated. Thomas Prevoznik, one unelected bureaucrat should not have the power to derail federally authorized drug development," said Duane Boise, CEO of MMJ International Holdings.
Duane Boise MMJ CEO stated "At the center of the MMJ cannabis pharmaceutical litigation sits DEA Thomas Prevoznik, an unearthed official with no medical or scientific expertise, who wields unchecked power to deny therapies under the guise of public safety."
“We are not just challenging DEA policy, we are defending the Constitution said Duane Boise, CEO of MMJ BioPharma Cultivation. The DEA cannot sidestep Supreme Court precedent and force us into a hearing. The agency is running a closed loop of power, Boise added, they investigate, prosecute, judge and override all in-house. That’s not justice, that’s a rigged game.”
Duane Boise CEO of MMJ International Holdings stated, “When private citizens or companies fall short of compliance, the DEA acts swiftly and decisively. The question is, why is there no comparable urgency when the failure comes from within the DEA's own ranks? The agency's silence on this matter is not just a public relations problem—it's a breach of public trust."
Central to the probe are DEA's Thomas Prevoznik, DEA's Matthew Strait and DEA attorney Aarathi Haig within the DEA's Diversion Control Division, whose conduct has raised serious questions about the integrity of the DEA's regulatory processes.
"This is insanity," declares Duane Boise, CEO of MMJ International Holdings, echoing the sentiments of lawmakers and researchers alike. The 2020 House Oversight Committee hearing, and ongoing developments, have laid bare the Drug Enforcement Administration's (DEA) persistent obstruction of legitimate cannabis research, a battle MMJ has been fighting since their 2018 application. Despite bipartisan congressional outrage, as highlighted by Representative Earl "Buddy" Carter's scathing critique of the DEA's "epitome of ineptitude," and the agency's own hollow defenses, the DEA, represented by figures like Matthew Strait and Thomas Prevoznik, continues to delay and deny, hindering vital medical advancements. Boise's lawsuit against the DEA underscores the urgent need for reform, as the agency's actions not only impede scientific progress but also deny patients access to potentially life-changing treatments, a situation that demands immediate structural changes in federal cannabis policy.
The DEA is "out of touch" and resistant to reform, stated Ben Kovler. Yet, amid this uncertainty, MMJ International Holdings has charted a distinct course-one rooted in pharmaceutical rigor-that's positioning the company as a trailblazer in the medical cannabis space.
The Department of Justice (DOJ) has announced that it will no longer defend statutory protections that currently shield Administrative Law Judges (ALJs) from removal. This significant shift is expected to bolster MMJ International Holdings' ongoing lawsuit against the Drug Enforcement Administration (DEA), which has been criticized for stalling MMJ's application to cultivate pharmaceutical-grade marijuana for medical research.
FDA-Compliant Clinical Trials:
MMJ's innovative soft gelatin THC-CBD capsule, known as MMJ-002, is undergoing the rigorous FDA approval process to validate the safety and efficacy of cannabis-derived therapeutics for use in human clinical trials for Huntington's disease patients.
MMJ is currently engaged in litigation with the Drug Enforcement Administration (DEA). The company contends that the DEA has obstructed domestic cannabis research despite the Right To Try and the Medical Marijuana Research Expansion Act. MMJ accuses the DEA of bias in restricting MMJ to cultivate its proprietary marijuana cultivars necessary for research and pharmaceutical drug manufacturing. A pending federal court ruling in Rhode Island will set a significant precedent, challenging DEA authority and potentially easing regulatory barriers for MMJ's future cannabinoid drug development.
DEA Admin Anne Milgram Resigns, Tom Prevoznik and Matt Strait Next? Bureaucratic Bias is Over.
DEA STYMIED MARIJUANA DRUG DEVELOPMENT - HOWEVER FDA MOVING FORWARD ON CANNABIS DRUG DEVELOPMENT FOR HUNTINGTON'S DISEASE
MMJ Submits FDA Investigational New Drug Application for Cannabis-Derived Drug
Duane Boise MMJ's CEO stated "The DEA's administrative law judge (ALJ) system has been accused of functioning as a ‘judge, jury, and executioner,’ with Anne Milgram the DEA's administrator controlling the prosecutorial and adjudicatory roles, raising concerns about due process and fairness for small entities like MMJ. As this case unfolds, the potential ramifications for the DEA's operations - and marijuana rescheduling hearings - are profound."
The DEA has violated the Controlled Substances Act (CSA) and the Medical Marijuana and Cannabidiol Research Expansion Act by failing to approve MMJ's marijuana research and cultivation application in a timely manner. Anne Milgram, DEA administrator, is responsible for the delays. MMJ claims the DEA has caused significant harm to suffering patients and financial damages to the company despite adhering to all the DEA regulatory requirements.
MMJ International Holdings has submitted to the FDA for approval of its soft gelatin capsule to be used in clinical trails for its Huntington Disease Study. MMJ has received an Orphan designation from the FDA. Once FDA approved the company will be one of a very few with federal authorization to sell its medication.
Milgram's public statements, juxtaposed with the DEA's restrictive actions, paint a picture of an agency at odds with itself-one that claims to prioritize public health while simultaneously obstructing access to innovative treatments that could save lives. As the legal and public pressure mounts, the DEA may be forced to reconsider its approach, leading to a new era of drug policy in America
Anne Milgram DEA Administrator Continues to Hinder Marijuana Research and Drug Development
DEA SUMMONS HAVE BEEN SERVED
Summons have been served on DEA officials, the Attorney General and the Administrative Law Judge to appear in Rhode Island federal court on MMJ's complaint.
Duane Boise, President of MMJ BioPharma Cultivation, stated, "I think most Americans want judges who don't mind telling the truth and don't mind saying we're wrong. Unlike the DEA's arrogant attitude of, if we make a mistake, we won't be called on it, however MMJ is doing exactly that. The most immature thing you can do is say, 'no, no, I didn't make a mistake.' The mature thing to do, that all adults learn to do in this country is to say, 'oops, that was a mistake. I'm going to fix it. I'm sorry.'"
Duane Boise President of MMJ companies applauded the supreme court ruling saying "after years of DEA gross misconduct and blatant misinterpretation of marijuana research and development policy the Constitution still matters. Now the DEA will have to clean up their in-house kangaroo court system to allow a fair and impartial administrative law hearing".
The court has issued summons to DEA Director Anne Milgram and other DEA personnel involved in the illegal appointments. This trial is poised to address the DEA's disregard for presidential and congressional marijuana laws and its manipulation of cases to the agency's favor.
NO FEDERAL MARIJUANA IS BEING GROWN
MMJ Marijuana Researcher Calls Biden's DEA a Rogue Law Enforcement Agency
Marijuana Rescheduling Process Normally Steered by the DEA had been taken over by the U.S. Justice Department. The decision would not be signed by DEA ANNE MILGRAM but by Attorney General Merrick Garland.